Monte Rosa announces first subjects dosed in Phase 1 study of MRT-8102

Monte Rosa Therapeutics (GLUE) announced that the first subjects have been dosed in a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1beta, and IL-6. Initial results from the Phase 1 study are expected in H1 2026. “The initiation of the MRT-8102 Phase 1 study represents another exciting step forward for our immunology and inflammation pipeline,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “MRT-8102 is the only clinical-stage MGD that selectively targets NEK7, a protein central to NLRP3 inflammasome activation and the downstream dysregulation of IL-1beta and IL-6 that underlie multiple inflammatory diseases.”